Roll-over Study to Allow Continued Access to Ribociclib
Status:
Not yet recruiting
Trial end date:
2027-11-02
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, roll-over study to evaluate the long term safety of
ribociclib in combination with other drugs in participants who are participating in a
Novartis sponsored global study, that has fulfilled requirements for its primary
objective(s), and who in the opinion of the Investigator, would benefit from continued
treatment.